Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by B. Basu
Start up in Textiles I Textile Value Chain, Textile Magazine
By B. Basu Introduction: The Textile Industry today:The textile industry is the most glorified and oldest industry in the world. After food, the cloth is necessary to cover the body and protect it from nature’s cold, rain, dust, summer, etc. It is the identification of one’s profession, such as police, school uniform, defense, medical profession, and so many more. It protects humans from any bacteria, disease, or pollution and covers the wound.
“Cosmic alternator” for the onset of large-scale magnetic fields
Topics Thermal conductivity, Magnetic fields, Magnetic reconnection, Plasma dynamics Magnetic reconnection processes have a key role to play in the development of important observed phenomena and events both in the laboratory and in space. The nature of these processes is radically different in the different physical regimes that are involved.
Early Phase Clinical Trial Designs - State of Play and Adapting for the Future
Publication HistoryPublished online: November 03, 2017Accepted: September 20, 2017; Received: September 14, 2017;
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)
Background: TP53 mutations are ubiquitous in HGSOC. APR-246 stabilises mutant p53 into wild-type conformation and through its active moiety MQ, also depletes glutathione and inhibits thioredoxin reductase. These mechanisms of action potentiate chemosensitivity of cancer cells. This study aimed to establish the recommended phase II dose (RPTD) of APR-246 in combination with C and PLD.
TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer U. Banerji1, B. Basu2, J.F. Spicer3, R. Wilson4, E. Hall1, R. Sundar1, S. Kumar2, Y. Wu3, V. Coyle4, S. Carreira1, M. Parmar1, J.C. Dawes1, S.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with B.
Contact B., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack